Sativex R&D

The currently approved Multiple Sclerosis indication for Sativex represents only the start of Sativex’s commercial life.

Beyond the approval for MS spasticity, GW is seeking to maximise the potential of Sativex through a comprehensive Phase III trials programme in cancer pain, funded by one of its licensing partners, Otsuka. This programme is targeted at the important US market but also provides an opportunity to address a major unmet need in other regions across the world. This Phase III programme follows positive results in two Phase II studies, which included over 500 patients in total.